Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00423293 · ClinicalTrials.gov registry record · Phase 2
Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer
A Phase 2 study of Anal Cancer, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 20
- Study locations
NCT00423293 is a Phase 2 study of Anal Cancer that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 63 participants, below the 577-participant average among 19 other Anal Cancer trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT00423293, a Phase 2 study of Anal Cancer, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as fluorouracil and mitomycin C, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with 5-fluorouracil (5-FU) and mitomycin C may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects and how well giving intensity-modulated radiation therapy together with fluorouracil and mitomycin C works in treating patients with invasive anal cancer.
Conditions Studied
Interventions
- RADIATION Intensity-modulated radiation therapy
- DRUG fluorouracil
- DRUG mitomycin C
Study Locations (20)
California
- Auburn Radiation Oncology - Auburn
- Providence Saint Joseph Medical Center - Burbank - Burbank
- Radiation Oncology Centers - Cameron Park - Cameron Park
- Mercy Cancer Center at Mercy San Juan Medical Center - Carmichael
- City of Hope Comprehensive Cancer Center - Duarte
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- Radiation Oncology Center - Roseville - Roseville
- Radiological Associates of Sacramento Medical Group, Incorporated - Sacramento
- Mercy General Hospital - Sacramento
- Solano Radiation Oncology Center - Vacaville
Colorado
- University of Colorado Cancer Center at UC Health Sciences Center - Aurora
- Penrose Cancer Center at Penrose Hospital - Colorado Springs
- Veterans Affairs Medical Center - Denver - Denver
- St. Mary - Corwin Regional Medical Center - Pueblo
Florida
- Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community Hospital - Boca Raton
- Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital - Fort Lauderdale
- Baptist Cancer Institute - Jacksonville - Jacksonville
Delaware
- Tunnell Cancer Center at Beebe Medical Center - Lewes
- CCOP - Christiana Care Health Services - Newark
Arizona
- Arizona Oncology - Tucson - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2006-12 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00423293
The ClinicalTrials.gov registry entry for NCT00423293 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 577-participant average among 19 other Anal Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Intensity-modulated radiation therapy is the first listed.
NCT00423293 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT00423293 about?
NCT00423293 is a clinical study titled "Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer". RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as fluorouracil and mitomycin C, work in different ways to stop the growth of tumor cells, either b...
What is the current status of trial NCT00423293?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2006-12. Estimated completion is 2016-12.
What conditions does trial NCT00423293 study?
This clinical trial studies the following conditions: Anal Cancer.
What interventions are being tested in trial NCT00423293?
The interventions under investigation include: Intensity-modulated radiation therapy (RADIATION), fluorouracil (DRUG), mitomycin C (DRUG).
Who is sponsoring clinical trial NCT00423293?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00423293 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
RECRUITING · Phase 2
-
REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation
ACTIVE NOT RECRUITING · Phase 2
-
Pembrolizumab in Metastatic Anal Cancer
COMPLETED · Phase 2
-
Assessing THE GAY Male Experience With Anal Cancer Prevention Strategies
RECRUITING
-
Self-sampling to Optimize Anal Lesion Outcomes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.